Lentiviral‐mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma

In our previous study, osteopontin (OPN) was identified as one of the leading genes that promote the metastasis of hepatocellular carcinoma (HCC). However, the mechanism by which OPN promotes metastasis of HCC is not understood. In this study, RNA interference mediated by viral vectors—which could induce a long‐lasting down‐regulation in gene expression—was applied to analyze the role of OPN in metastasis of HCC. Three lentiviral vectors encoding microRNA against OPN, Lenti.OPNi‐1, Lenti.OPNi‐2, and Lenti.OPNi‐3, were constructed and found to down‐regulate the OPN level by 62%, 78%, and 95%, respectively, in HCCLM3 cells which had an overexpression of OPN and a higher metastatic potential. Consequently, both Lenti.OPNi‐2 and Lenti.OPNi‐3 induced a significant decrease in matrix metalloproteinase (MMP)‐2 and urokinase plasminogen activator expression, and led to an obvious inhibition of both in vitro invasion and in vivo lung metastasis of HCCLM3 cells (P < 0.001). Moreover, Lenti.OPNi‐3, rather than Lenti.OPNi‐2, could also suppress in vitro proliferation and in vivo tumor growth of HCCLM3. Smaller detectable tumors were found in only 50% of mice after implantation of Lenti.OPNi‐3–transfected HCCLM3 cells (341 ± 502.6 mm3 versus >3500 mm3 in controls; P < 0.001). Lenti.OPNi‐3, not Lenti.OPNi‐2, significantly suppressed the MEK/ERK1/2 pathway in HCCLM3 cells. Recombinant OPN was found to induce translocation of p65 into the nucleus of HCC cells and activation of MMP‐2 and MEK/ERK/1/2, which were suppressed by the nuclear factor κB (NF‐κB) inhibitor pyrrolidine dithiocarbamate. Conclusion: OPN plays an important role in metastasis as well as tumor growth of HCC, in which different minimum threshold levels of OPN are needed. These effects may occur through activation of the mitogen‐activated protein kinase and NF‐κB pathways, and MMP‐2. OPN could be a hopeful target for the control of HCC. (HEPATOLOGY 2008;48:1834‐11842.)

[1]  H. Huynh,et al.  Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma , 2007, Molecular Cancer Therapeutics.

[2]  S. Rittling,et al.  Osteopontin expression in mammary gland development and tumorigenesis. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[3]  G. Casey,et al.  Osteopontin Knockdown Suppresses Tumorigenicity of Human Metastatic Breast Carcinoma, MDA-MB-435 , 2006, Clinical & Experimental Metastasis.

[4]  I. McKillop,et al.  Increased MAPK expression and activity in primary human hepatocellular carcinoma. , 1997, Biochemical and biophysical research communications.

[5]  L. Qin,et al.  Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature , 2004, Journal of Cancer Research and Clinical Oncology.

[6]  L. Qin,et al.  High‐lose and long‐term therapy with interferon‐alfa inhibits tumor growth and recurrence in nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential , 2000, Hepatology.

[7]  J. Sebolt-Leopold,et al.  The effects of a novel MEK inhibitor PD184161 on MEK-ERK signaling and growth in human liver cancer. , 2006, Neoplasia.

[8]  A. Peri,et al.  Potential roles of osteopontin and αVβ3 integrin in the development of coronary artery restenosis after angioplasty , 1997 .

[9]  M. Yamamoto,et al.  Genetic and epigenetic events in human hepatocarcinogenesis. , 2001, International journal of oncology.

[10]  P. Kuo,et al.  Osteopontin: regulation in tumor metastasis , 2008, Cancer and Metastasis Reviews.

[11]  S. Philip,et al.  Osteopontin Stimulates Tumor Growth and Activation of Promatrix Metalloproteinase-2 through Nuclear Factor-κB-mediated Induction of Membrane Type 1 Matrix Metalloproteinase in Murine Melanoma Cells* , 2001, The Journal of Biological Chemistry.

[12]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[13]  H. Hsu,et al.  Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma , 2003, Cancer.

[14]  G. Kundu,et al.  Osteopontin Induces Nuclear Factor κB-mediated Promatrix Metalloproteinase-2 Activation through IκBα/IKK Signaling Pathways, and Curcumin (Diferulolylmethane) Down-regulates These Pathways* , 2003, The Journal of Biological Chemistry.

[15]  B. Hogan,et al.  Altered wound healing in mice lacking a functional osteopontin gene (spp1). , 1998, The Journal of clinical investigation.

[16]  G. Kundu,et al.  Osteopontin induces nuclear factor kappa B-mediated promatrix metalloproteinase-2 activation through I kappa B alpha /IKK signaling pathways, and curcumin (diferulolylmethane) down-regulates these pathways. , 2003, The Journal of biological chemistry.

[17]  G. Kundu,et al.  Osteopontin: role in cell signaling and cancer progression. , 2006, Trends in cell biology.

[18]  Jiang He,et al.  Major causes of death among men and women in China. , 2005, The New England journal of medicine.

[19]  M. Noda,et al.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. , 2001, The Journal of clinical investigation.

[20]  X. Wang,et al.  Predicting hepatitis B virus–positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning , 2003, Nature Medicine.

[21]  M. Vidaud,et al.  Pravastatin reduces lung metastasis of rat hepatocellular carcinoma via a coordinated decrease of MMP expression and activity. , 2007, Journal of hepatology.

[22]  Robert H. Silverman,et al.  Activation of the interferon system by short-interfering RNAs , 2003, Nature Cell Biology.

[23]  G. Tiberio,et al.  Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications , 2006, Annals of surgery.

[24]  S. Ye,et al.  New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis , 1999, British Journal of Cancer.

[25]  P. Kuo,et al.  The role of Osteopontin in tumor metastasis. , 2004, The Journal of surgical research.

[26]  J. Liu,et al.  Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[27]  S. Elledge,et al.  A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  A. Hada,et al.  Genetic and epigenetic events in human hepatocarcinogenesis (review) , 2001 .

[29]  M. Stack,et al.  Intact Vitronectin Induces Matrix Metalloproteinase-2 and Tissue Inhibitor of Metalloproteinases-2 Expression and Enhanced Cellular Invasion by Melanoma Cells* , 1998, The Journal of Biological Chemistry.

[30]  Hong Wu,et al.  Increased expression of osteopontin contributes to the progression of prostate cancer. , 2006, Cancer research.

[31]  I. McKillop,et al.  Altered expression of mitogen‐activated protein kinases in a rat model of experimental hepatocellular carcinoma , 1997, Hepatology.

[32]  A. Peri,et al.  Potential roles of osteopontin and alphaVbeta3 integrin in the development of coronary artery restenosis after angioplasty. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[33]  H. Adwan,et al.  Downregulation of osteopontin and bone sialoprotein II is related to reduced colony formation and metastasis formation of MDA-MB-231 human breast cancer cells , 2004, Cancer Gene Therapy.

[34]  H. Yokozaki,et al.  Co‐expression of osteopontin and CD44v9 in gastric cancer , 1998, International journal of cancer.

[35]  Vivek Mittal,et al.  Improving the efficiency of RNA interference in mammals , 2004, Nature Reviews Genetics.

[36]  G. Kundu,et al.  Osteopontin Stimulates Cell Motility and Nuclear Factor κB-mediated Secretion of Urokinase Type Plasminogen Activator through Phosphatidylinositol 3-Kinase/Akt Signaling Pathways in Breast Cancer Cells* , 2003, Journal of Biological Chemistry.

[37]  M. Takamura,et al.  Overexpression of extracellular signal‐regulated protein kinase and its correlation with proliferation in human hepatocellular carcinoma , 2004, Liver international : official journal of the International Association for the Study of the Liver.

[38]  M. Trikha,et al.  Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: differences in integrin signaling during cell adhesion to osteopontin versus vitronectin. , 2002, Cancer research.

[39]  Q. Ye,et al.  The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma , 2006, Journal of Cancer Research and Clinical Oncology.

[40]  G. de Rosa,et al.  Overexpression of the Cytokine Osteopontin Identifies Aggressive Laryngeal Squamous Cell Carcinomas and Enhances Carcinoma Cell Proliferation and Invasiveness , 2005, Clinical Cancer Research.

[41]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[42]  Yan Li,et al.  Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics , 2004, Journal of Cancer Research and Clinical Oncology.

[43]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.